Amicus Therapeutics fat disorder drug effective in trial
April 29 (Reuters) - Amicus Therapeutics Inc said its lead drug to treat fat-storage disorder was found effective in patients after 12 months of treatment in a late-stage trial.
The company's shares jumped about 33 percent in premarket trading. They closed at $1.84 on the Nasdaq on Monday.
The trial evaluated the drug, migalastat, as a form of monotherapy for Fabry disease patients. (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)
- NOAA employee charged with stealing U.S. dam information
- Autopsy of slain Missouri teen shows close-range gunshot: report
- Special Report: Traffickers use abductions, prison ships to feed Asian slave trade
- Hong Kong protesters march after fruitless talks with government
- Sweden gets two new sightings, as hunt for undersea intruder goes on